|
Defining mechanisms of cancer chemoresistance and metastasis
|
5R00CA172697-03
|
$249,000
|
$249,000
|
ACHARYYA, SWARNALI
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Center for Multiple Myeloma Nanotherapy
|
1U54CA199092-01
|
$2,256,089
|
$1,601,823
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-15
|
$1,428,925
|
$85,736
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
SPARC as a regulator of collagen signaling in Pancreatic Cancer
|
5F31CA168350-03
|
$30,485
|
$7,621
|
AGUILERA, KRISTINA
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
3U54CA137788-08S1
|
$200,000
|
$24,000
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
CCNY-MSKCC Partnership for Cancer Research Training & Community Outreach (1 of 2
|
5U54CA137788-08
|
$1,073,287
|
$128,794
|
AHLES, TIM
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Inhibition of Hedgehog Signaling in Gli-1+Adeno CA of the Esoph or GE junction
|
5R01CA172741-03
|
$279,793
|
$279,793
|
AJANI, JAFFER
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Molecular Interaction Maps and Analysis of Bioregulatory Networks
|
ZIA BC 010562
|
$42,675
|
$2,134
|
Aladjem, Mirit
|
CCR (NCI)
|
|
Immuno/Immuno-Gene Therapies for Thoracic Malignancies
|
5P01CA066726-18
|
$1,182,811
|
$224,734
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Use of Genetically Engineered T cells Targeting Tumor Stroma to Treat Lung Cancer
|
5R01CA172921-03
|
$357,673
|
$178,837
|
ALBELDA, STEVEN
|
UNIVERSITY OF PENNSYLVANIA
|
|
Combined Acoustic Imaging and Viscoelastic Parameters Estimation in Breast Cancer
|
3R01CA148994-05S1
|
$96,798
|
$48,399
|
ALIZAD, AZRA
|
MAYO CLINIC ROCHESTER
|
|
Combined Acoustic Imaging and Viscoelastic Parameters Estimation in Breast Cancer
|
5R01CA148994-05
|
$390,161
|
$195,081
|
ALIZAD, AZRA
|
MAYO CLINIC ROCHESTER
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-02
|
$423,409
|
$139,725
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Therapeutic resistance in leukemic cells: targeting BCL-2 family and autophagy
|
1R01CA184137-01A1
|
$362,569
|
$362,569
|
ALMASAN, ALEXANDRU
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics
|
1U01CA202144-01
|
$607,358
|
$607,358
|
ALTER, ORLY
|
UNIVERSITY OF UTAH
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-46S1
|
$138,748
|
$5,550
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-46
|
$2,578,347
|
$103,134
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Markers for Disease Outcome in Breast Cancer
|
ZIA BC 010887
|
$483,603
|
$96,721
|
Ambs, Stefan
|
CCR (NCI)
|
|
Novel Dual Notch/PXR Targeting for Colon Cancer Therapy
|
5R01CA182872-02
|
$67,777
|
$67,777
|
ANANT, SHRIKANT
|
UNIVERSITY OF KANSAS MEDICAL CENTER
|
|
PARP Inhibition to Treat Triple-Negative Breast Cancer Brain Metastases
|
5K23CA157728-05
|
$173,598
|
$173,598
|
ANDERS, CAREY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Sensitization to CD47 Blockade to Enhance Anti-Tumor Immunity
|
1F30CA195973-01
|
$41,990
|
$41,990
|
ANDERSON, KATIE
|
UNIVERSITY OF MINNESOTA
|
|
SPORE in Multple Myeloma
|
5P50CA100707-13
|
$2,185,000
|
$1,311,000
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
5R01CA050947-23
|
$301,545
|
$150,773
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Clinical trials in women's cancers
|
ZIA BC 011584
|
$174,715
|
$87,357
|
Annunziata, Christina
|
CCR (NCI)
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$558,424
|
$251,291
|
Apolo, Andrea
|
CCR (NCI)
|
|
Longitudinal Cardiotoxicity in Adult Survivors Childhood Cancer
|
5R01CA157838-04
|
$600,509
|
$600,509
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Targeting to Epigenetic Modications in ALL
|
5R01CA176745-05
|
$402,250
|
$402,250
|
ARMSTRONG, SCOTT
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Childhood Cancer Survivor Study
|
5U24CA055727-21
|
$4,271,782
|
$1,708,713
|
ARMSTRONG, GREGORY
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
SPORE in Breast Cancer
|
5P50CA098131-13
|
$2,185,000
|
$546,250
|
ARTEAGA, CARLOS
|
VANDERBILT UNIVERSITY
|
|
Image-guided combination therapy: noninvasive assessment of delivery and response
|
5R01CA154738-05
|
$562,844
|
$562,844
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA082103-17S2
|
$50,000
|
$6,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S3
|
$124,967
|
$14,996
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S4
|
$199,969
|
$23,996
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-17S5
|
$158,600
|
$19,032
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
5P30CA082103-17
|
$7,292,969
|
$875,156
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
A Prospective Study of the Impact of Breast Cancer on Symptoms and Functioning
|
1R01CA199137-01
|
$424,296
|
$140,018
|
AVIS, NANCY
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
PET Kinetic Modeling of Inhibiting Glycolysis in Ovarian Cancer
|
1R21CA198795-01
|
$185,247
|
$185,247
|
AVRIL, NORBERT
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Using FAP to Selectively Target Epithelial Cancers
|
5R01CA163930-04
|
$349,435
|
$174,718
|
BACHOVCHIN, WILLIAM
|
TUFTS UNIVERSITY BOSTON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-41S1
|
$37,429
|
$1,123
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
3P30CA014520-41S2
|
$125,000
|
$3,750
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive Cancer Center Support
|
5P30CA014520-41
|
$4,288,496
|
$128,655
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Normal and Neoplastic Growth in the Brain
|
2P01CA096832-11A1
|
$2,082,888
|
$291,604
|
BAKER, SUZANNE
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
2R01CA138744-06A1
|
$314,867
|
$314,867
|
BAKER, SHARYN
|
OHIO STATE UNIVERSITY
|
|
Interferon Activated Necroptosis as a New Therapeutic Avenue for Kidney Cancer
|
5R01CA168621-02
|
$370,388
|
$370,388
|
BALACHANDRAN, SIDDHARTH
|
RESEARCH INST OF FOX CHASE CAN CTR
|
|
A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma
|
5R44CA159843-03
|
$740,587
|
$740,587
|
BALHORN, RODNEY
|
SHAL TECHNOLOGIES, INC.
|
|
Dusp4 in breast cancer: tumor suppressor biology and therapeutic strategies
|
4R00CA181491-02
|
$249,000
|
$124,500
|
BALKO, JUSTIN
|
VANDERBILT UNIVERSITY
|
|
Targeting Androgen Receptor Pathway in a Subset of Triple Negative Breast Cancer
|
1F31CA192807-01
|
$31,549
|
$31,549
|
BARTON, VALERIE
|
UNIVERSITY OF COLORADO DENVER
|
|
ARHI (DIRAS3) in Autophagy and Dormancy of Ovarian Cancer
|
2R01CA135354-05
|
$380,000
|
$380,000
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-15S1
|
$901,656
|
$54,099
|
BAST, ROBERT
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
Training Program in Nervous System Tumors
|
5K12CA090354-15
|
$774,522
|
$387,261
|
BATCHELOR, TRACY
|
MASSACHUSETTS GENERAL HOSPITAL
|
Total relevant funding to Chemotherapy for this search: $267,914,843
|